Previous 10 | Next 10 |
Vertex Energy (VTNR) +98% on deal for Shell's Mobile refinery.Moxian (MOXC) +37%.1847 Goedeker (GOED) +22%.SOS Limited (SOS) +14%.Bit Digital (BTBT) +13%.Vir Biotechnology (VIR) +9% as GSK/Vir COVID-19 biologic wins FDA Emergency Use Authorization.LAIX (LAIX) +12% on Q1 results...
PRINCETON, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the company will be participating virtually in the William Blair 41 st Annual Growth Stock Conference. Chairman and Chief Executive Offic...
PRINCETON, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the 2021 RBC Capital Markets Global ...
Agile Therapeutics recently reported a mixed Q1 earnings with a slight beat on EPS and a miss on revenue. However, the company's earnings call has reignited my bullish outlook. Q1 was Twirla's first quarter on the market and its sales numbers were not very impressive. Consequently, th...
The following slide deck was published by Agile Therapeutics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Agile Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
Image source: The Motley Fool. Agile Therapeutics (NASDAQ: AGRX) Q1 2021 Earnings Call May 04, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Agile Therapeutics (AGRX) Q1 2021 Earnings Call Transcript
Agile Therapeutics, Inc. (AGRX) Q1 2021 Earnings Conference Call May 04, 2021, 16:30 ET Company Participants Matthew Riley - Head, IR & Corporate Communications Alfred Altomari - Chairman & CEO Dennis Reilly - SVP & CFO Conference Call Participants Oren Livnat - H.C. Wainwright &a...
Agile Therapeutics (AGRX): Q1 GAAP EPS of -$0.20 beats by $0.01.During the first quarter 2021, total prescriptions were 1,853. The growth was driven by an increase in the number of prescribers, which as of March 31, 2021 was more than 850 HCPs, and growing refill rates. As of March 31, 2021, ...
Prescription Growth Reflects Increasing Demand for Twirla Base of Prescribers Continues to Grow in First Quarter 2021 Growing Distribution Network and Marketing Efforts Expected to Drive Healthcare Provider and Consumer Engagement PRINCETON, N.J., May 04, 2021 ...
PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial evaluating the safety and efficacy of Twirla ® (levonorgestrel and ethinyl estra...
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
NASDAQ Market:
Agile Therapeutics Inc. Website:
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2...